1. Advani A, Marsh C, Ashworth LE. Medical information support of the sales force: an external and internal assessment. Drug Inf J. 2010;44:685–691.
2. Salter FJ, Kramer PF, Palmer-Shevlin NL. Pharmaceutical industry medical communications departments: regulatory and legal perils and pitfalls. Drug Inf J. 2000;34:1009–1115.
3. Rehnquist J. US Office of the Inspector General (OIG): compliance program guidance for pharmaceutical manufacturers. Fed Regist. 2003;68:23731–23743. Available at: https://oig.hhs.gov/fraud/docs/complianceguidance/042803pharmacymfgnonfr.pdf. Accessed June 25, 2013.
4. Kux L. US Food and Drug Administration: guidance for industry. Responding to unsolicited requests for off-label information about prescription drugs and medical devices. Fed Regist. 2011;76:82303–82306. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM285145.pdf?source=govdelivery. Accessed June 25, 2013.
5. Sandburg B. Amgen off-label settlement includes exec oversight of individual product compliance. The Pink Sheet. Dec 24, 2012. Article # 00121224014 (online edition).